Biological shares: Intending to subscribe for 50 million yuan of private equity fund shares.

The biological stock announcement stated that its wholly-owned subsidiary, Jinyu Baoling, plans to use its own funds of 50 million yuan to subscribe to the Morning Glory Core 2 Private Equity Securities Investment Fund. The fund was established on February 3, 2026, with a term of 20 years, managed by Morning Glory (Shenzhen) Private Equity Securities Investment Fund Management Co., Ltd., and entrusted by Guotai Haitong Securities Co., Ltd. This investment is within the company's operating level approval authority, does not constitute related party transactions or major asset restructuring. The fund does not have a capital guarantee or minimum return commitment. The company will closely monitor its operation and control investment risks.